Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?

[Image: see text] Inhaled siRNA therapy has a unique potential for treatment of severe lung diseases, such as cystic fibrosis (CF). Nevertheless, a drug delivery system tackling lung barriers is mandatory to enhance gene silencing efficacy in the airway epithelium. We recently demonstrated that lipi...

Descripción completa

Detalles Bibliográficos
Autores principales: Conte, Gemma, Costabile, Gabriella, Baldassi, Domizia, Rondelli, Valeria, Bassi, Rosaria, Colombo, Diego, Linardos, Giulia, Fiscarelli, Ersilia V., Sorrentino, Raffaella, Miro, Agnese, Quaglia, Fabiana, Brocca, Paola, d’Angelo, Ivana, Merkel, Olivia M., Ungaro, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855343/
https://www.ncbi.nlm.nih.gov/pubmed/35107987
http://dx.doi.org/10.1021/acsami.1c14975

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8855343/
https://www.ncbi.nlm.nih.gov/pubmed/35107987
http://dx.doi.org/10.1021/acsami.1c14975

Ejemplares similares